Kanvas Biosciences: Revolutionizing Cancer Treatment with Microbiome-Based Therapies
July 4, 2024, 3:34 pm
Kanvas Biosciences, a cutting-edge spatial biology company based in Princeton, NJ, has recently secured an additional $12.5 million in funding to advance its groundbreaking microbiome-based immuno-oncology drug candidates. This latest funding round, led by DCVC and Lions Capital LLC, with participation from FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures, brings the total funding for Kanvas Biosciences to an impressive $29.5 million.
The company's proprietary spatial biology platform is at the forefront of innovation in drug development, clinical diagnostics, agriculture, and food safety. By leveraging the microbiome, a crucial factor in human health, Kanvas Biosciences aims to manufacture therapeutics that hold significant promise for improving outcomes in ICI-refractory cancers.
Kanvas Biosciences' lead drug candidate, KAN-001, is a live biotherapeutic product (LBP) that shows remarkable potential to enhance treatment efficacy for cancer patients who have not responded to immune checkpoint inhibitors (ICIs). The company's second drug candidate, KAN-003, is a defined consortium designed to be administered prior to ICI treatment, with the goal of increasing response rates across various cancer types.
In collaboration with The University of Texas MD Anderson Cancer Center and its Platform for Innovative Microbiome and Translational Research (PRIME-TR), Kanvas Biosciences is conducting preclinical studies to optimize the formulation of KAN-001 and prepare it for an Investigational New Drug (IND) filing in 2025. This milestone will pave the way for the recruitment of the first patients for a clinical trial later that year.
The company's spatial biology platform offers a unique ability to map host-microbiome interactions, providing valuable insights into the complex relationship between microbial communities and human health. By developing complex microbial consortia containing multiple bacterial strains, Kanvas Biosciences aims to create more effective live biotherapeutics that target microbiome-related conditions such as solid organ cancer, inflammatory bowel disease, and metabolic disorders.
With a market projected to grow at a 21% compound annual growth rate (CAGR) to over $3 billion by 2031, live biotherapeutic products (LBPs) represent a promising avenue for improving treatment outcomes in microbiome-associated diseases. Kanvas Biosciences' innovative approach to LBP development, focusing on complex microbial consortia and advanced AI integration, sets the company apart in the field of microbiome-based therapies.
The recent expansion of Kanvas Biosciences' leadership team and the opening of a new research laboratory and drug manufacturing facility in South San Francisco underscore the company's commitment to advancing microbiome-based therapies. With a mission to accelerate the development of next-generation live biotherapeutics, Kanvas Biosciences is poised to revolutionize cancer treatment and improve the lives of patients worldwide.
For more information on Kanvas Biosciences and its pioneering work in microbiome-based therapies, visit their website at https://www.kanvasbio.com/.
The company's proprietary spatial biology platform is at the forefront of innovation in drug development, clinical diagnostics, agriculture, and food safety. By leveraging the microbiome, a crucial factor in human health, Kanvas Biosciences aims to manufacture therapeutics that hold significant promise for improving outcomes in ICI-refractory cancers.
Kanvas Biosciences' lead drug candidate, KAN-001, is a live biotherapeutic product (LBP) that shows remarkable potential to enhance treatment efficacy for cancer patients who have not responded to immune checkpoint inhibitors (ICIs). The company's second drug candidate, KAN-003, is a defined consortium designed to be administered prior to ICI treatment, with the goal of increasing response rates across various cancer types.
In collaboration with The University of Texas MD Anderson Cancer Center and its Platform for Innovative Microbiome and Translational Research (PRIME-TR), Kanvas Biosciences is conducting preclinical studies to optimize the formulation of KAN-001 and prepare it for an Investigational New Drug (IND) filing in 2025. This milestone will pave the way for the recruitment of the first patients for a clinical trial later that year.
The company's spatial biology platform offers a unique ability to map host-microbiome interactions, providing valuable insights into the complex relationship between microbial communities and human health. By developing complex microbial consortia containing multiple bacterial strains, Kanvas Biosciences aims to create more effective live biotherapeutics that target microbiome-related conditions such as solid organ cancer, inflammatory bowel disease, and metabolic disorders.
With a market projected to grow at a 21% compound annual growth rate (CAGR) to over $3 billion by 2031, live biotherapeutic products (LBPs) represent a promising avenue for improving treatment outcomes in microbiome-associated diseases. Kanvas Biosciences' innovative approach to LBP development, focusing on complex microbial consortia and advanced AI integration, sets the company apart in the field of microbiome-based therapies.
The recent expansion of Kanvas Biosciences' leadership team and the opening of a new research laboratory and drug manufacturing facility in South San Francisco underscore the company's commitment to advancing microbiome-based therapies. With a mission to accelerate the development of next-generation live biotherapeutics, Kanvas Biosciences is poised to revolutionize cancer treatment and improve the lives of patients worldwide.
For more information on Kanvas Biosciences and its pioneering work in microbiome-based therapies, visit their website at https://www.kanvasbio.com/.